Oral News and Research

RSS

Prevalence of oral HPV infection more common among men: Study

Oral HPV infection is more common among men than women, explaining why men are more prone than women to develop an HPV related head and neck cancer, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

27 Jan 2012

Viewpoints: Health care is MIA in the State of the Union; Gingrich's earnings for health views

President Obama's largest legislative accomplishment to date was the passage of the health care reform law, which has been going into effect in stages, with regulations currently being written for the most substantial changes due to take effect in 2014. So it is odd the President mentioned health care only briefly, and in passing, in his State of the Union address last night.

27 Jan 2012

FDA approves UCB's Keppra for treatment of partial onset seizures in infants

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in the treatment of partial onset seizures in adults and children one month of age and older with epilepsy.

27 Jan 2012

New consensus guidelines for treatment of plaque psoriasis

To assist the millions of Americans living with psoriasis, the most common autoimmune disease in the country, the National Psoriasis Foundation published the most recent guidelines in the United States for the management of plaque psoriasis—the most prevalent form of the disease, affecting roughly 80 percent of people with psoriasis.

26 Jan 2012

Oramed receives Australian patent for core technology in oral delivery of peptides

Marking a major milestone for the Company, Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Australian Patent Office.

25 Jan 2012

Society for Endocrinology BES conference to take place March 19-22

The annual Society for Endocrinology BES conference is taking place in Harrogate, UK from 19-22 March 2012.

25 Jan 2012

High court rejects request for debate over Elena Kagan's recusal from health law review

The justices, who are scheduled to hear more than five hours of arguments challenging the health law, turned down the request without comment. Kagan did not participate in the decision.

25 Jan 2012

Glanbia Nutritionals, ChromaDex sign LOI for pTeroPure

ChromaDex Corporation, an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of its branded patent-pending pterostilbene, pTeroPure, announced today it has signed a letter of intent with Glanbia Nutritionals (NA), Inc., a global ingredient and micronutrient premix company, for the distribution of pTeroPure. Glanbia Nutritionals will serve as the primary distributor of pTeroPure in North America.

25 Jan 2012

OraQuick HIV1/2 test as accurate as traditional blood test

A saliva test used to diagnose the human immunodeficiency virus (HIV), is comparable in accuracy to the traditional blood test, according to a new study led by the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University.

25 Jan 2012

Aphios receives NIH's Phase II SBIR grant to develop APH-0703 for AD

Aphios Corporation has received a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to the Aphios Corporation to develop an "Alzheimer's Disease Therapeutic."

24 Jan 2012

Genoscience, BioLineRx to develop and commercialize BL-8020 for HCV

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience, a French company focused on viral disease therapeutics, to develop and commercialize BL-8020, an orally available treatment for Hepatitis C.

24 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

Mass. Gov. again seeks health insurance payment overhaul; Iowa lawmakers review denial of health coverage to residents with HIV

Articles detail the Massachusetts state of the state address, efforts in Iowa to probe denials in the high risk pool and other legislative news.

24 Jan 2012

Multidisciplinary Head and Neck Cancer Symposium hosts research briefings

The Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM, will host two news briefings on top head and neck cancer research from its meeting January 26-28, 2012, in Phoenix.

24 Jan 2012

CAFC to rehear en banc HemCon's patent infringement appeal

HemCon Medical Technologies, Inc., announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) will rehear en banc HemCon's appeal of the patent infringement case brought by Marine Polymer Technologies, Inc.

24 Jan 2012

Viewpoints: Opposing views of HHS' contraception rule; Health care costs and the liberal agenda

The administration's rule leaves the decision in the hands of patients, where it belongs, while respecting the rights of religions. It holds true to the original and wise idea that access to preventive medicine is a good idea for the nation's physical and financial well-being.

24 Jan 2012

PERC-led study recognized as one of Canada's top achievements in health research

You could call it paying it forward. A trip to the Emergency Department (ED) is every parent's worst nightmare. But what if the information documented as a result of your child's visit could help a child with similar symptoms a few provinces away? Terry Klassen and his research team of leading pediatric emergency physicians at Pediatric Emergency Research of Canada (PERC) have done just that and the impact of their research is today recognized as one of the Top Canadian Achievements in Health Research in 2011.

24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

The US Food and Drugs Administration (FDA) and European Medicines Agency (EMA) are looking at the pros and cons of using Gilenya (fingolimod) in treating the neurological autoimmune disease Multiple Sclerosis (MS).

23 Jan 2012

New tool to improve ease of oral fluid collection

Researchers are constantly finding new ways to figure out what makes us human beings tick, and one of the newer methods makes you want to spit—literally. Saliva is full of analytes and biomarkers that create a biological journal of exposure to chemicals and disease, and genetic variability. However, the collection of oral fluid has always proved cumbersome, with researchers depending on swabs or collection cups.

21 Jan 2012